Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • FBIOP Announcements
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor

Jan 07, 2016

Avenue Therapeutics Files to Become a Public Reporting Company

Dec 30, 2015

Checkpoint Therapeutics Closes $58M in Private Placement Financing

Dec 21, 2015

Fortress Biotech Reports Financial Results for the Third Quarter 2015 Ended September 30, 2015

Nov 09, 2015

Checkpoint Therapeutics Announces Appointment of James F. Oliviero, III, as President & Chief Executive Officer

Oct 16, 2015

Checkpoint Therapeutics Files to Become a Public Reporting Company

Sep 08, 2015

Fortress Biotech Reports Financial Results for the Second Quarter 2015 Ended June 30, 2015

Aug 10, 2015

Fortress Biotech Subsidiary, Altamira Bio, Acquires NIH License and CRADAs Relating to the Development of N-acetyl-D-mannosamine (ManNAc) for Rare Genetic Disorders

Jul 17, 2015

Fortress Biotech Reports Financial Results for the First Quarter 2015 Ended March 31, 2015

May 11, 2015
RSS
  • Prev
    • 1...
    • 61
    • 62
    • 63
    • 64
    • 65
    • 66
    • 67
    • 68
    • 69
    • 70
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap